en · de · es · fr · pt
aod-9604-notes.peptides6155.com › Info › Research And Regulatory Status — Quick Reference

Research And Regulatory Status — Quick Reference

By Editorial Desk · published 2026-04-14 · last reviewed 2026-05-15 · Info

AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-05-15. Where a claim depends on a specific study, the study is described rather than over-claimed.

Research and Regulatory Status

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Handling And Analytical Properties

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Related pages on this site

Identity And Research Background

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

Reference notes

The Prachachat Party issued a statement asking the Election Commission to investigate irregularities in Pattani and Narathiwat Constituency 4, and the Bhumjaithai candidate in Narathiwat Constituency 3 asked for a recount in that constituency. Former Election Commission member Somchai Srisutthiyakorn criticized the commission's failure to comply with regulations in Chonburi Constituency 1, stating that election showed serious signs of fraud. He further stated that even a recount might not be enough due to the possibility of tampering with improperly sealed boxes and suggested that a repeat election might have to be held in the constituency. On 12 February, the Election Commission rejected the requests for recounts in Chonburi and Maha Sarakham, stating that its investigation did not find credible evidence. In the same press briefing, it ordered new elections for three polling stations: one in Bangkok where ballots were damaged by rain, and two in Nan and Udon Thani, where polling station officials incorrectly tore ballots. It also ordered a recount of the votes in Pathum Thani Constituency 7, which had been subject to complaints that officials failed to properly count votes in view of the public. Further recounts at eight stations and a fresh election at one station were announced on 17 February, and nine more on 24 February.

The citric acid cycle is regulated mainly by the availability of key substrates, particularly the ratio of NAD+ to NADH and the concentrations of calcium, inorganic phosphate, ATP, ADP, and AMP. Citrate – the ion that gives its name to the cycle – is a feedback inhibitor of citrate synthase and also inhibits PFK, providing a direct link between the regulation of the citric acid cycle and glycolysis.

Many drugs are metabolised by a set of liver enzymes called CYP450s. The activity of these enzymes would determine the rate of pro-drug activation and the rate of inactivation of active drugs. For example, warfarin, a commonly used anticoagulant drug in atrial fibrillation, is metabolised by an enzyme called CYP2C9. Phenytoin, a CYP2C9 inducer, would increase its activity and the rate of warfarin breakdown, thereby reducing its efficacy. Patients should avoid the co-administration of warfarin and phenytoin. In cases where both drugs must be used together, warfarin dosing may be titrated up to cope with the reduced efficacy. The kidney excretes most drugs through urine. Since urine is weakly alkaline in nature, weakly acid drugs would ionise in urine, making it difficult for them to be reabsorbed. Therefore, in cases of aspirin (weak acid) toxicity, injecting intravenous sodium bicarbonate could increase urine pH, thereby increasing the excretion of aspirin through urine. A similar approach can be used in other weakly acidic drug toxicity.

12(S)-HpETE, 12(R)-HETE, racemic mixtures of these 12-HETEs, and/or 12-oxo-ETE stimulate: a) the directed migration (chemotaxis) of human, rat, and rabbit neutrophils as well as rabbit macrophages; b) human neutrophils to adhere to each other (i.e. aggregate) and in cooperation with tumor necrosis factor alpha or platelet-activating factor, to release their granule-bound enzymes; c) the binding of human vascular epithelial cells to human monocytes; d) DNA synthesis and mitogenesis in the immortalized human keratinocyte cell line HaCaT; and e) when injected in the skin of human volunteers, the extravasation and local accumulation of circulating blood neutrophils and mononuclear cells. These results suggest these metabolites contribute to the inflammation that occurs at sites where they are formed in abnormal amounts such as in human rheumatoid arthritis, inflammatory bowel disease, contact dermatitis, psoriasis, various forms of ichthyosis including congenital ichthyosiform erythroderma, and corneal inflammatory diseases. Since BLT2 appears to mediate the responses of leukocytes to 12(S)-HpETE, 12(S)-HETE, 12(R)-HETE, and 12-oxo-ETE but GPR31 is expressed by various other cells (e.g. vascular endothelium) involved in inflammation, the pro-inflammatory actions of 12-HETE in humans may involve both types of G protein-coupled receptors.

Sources: en.wikipedia.org

Reference notes

At the time of Exubera's discontinuation, several other companies were pursuing inhaled insulin including Alkermes working with Eli Lilly and Company, MannKind Corporation, and Aradigm working with Novo Nordisk. By March 2008, except for MannKind's Afrezza product, all of these products had been discontinued because investors all decided to withdraw funding. On March 16, 2009, MannKind submitted a new drug application for their inhalable insulin. In 2011, the FDA denied approval of Afrezza; because the design of the delivery device had changed, it requested additional clinical trials to ensure that people would use it the same way as the earlier versions. After conducting further studies, Mannkind submitted a new application, and in June 2014, the FDA approved Afrezza for both type 1 and type 2 adult diabetics, with a label restriction for patients having asthma, active lung cancer, or COPD. In 2014, Mannkind and Sanofi agreed that Sanofi would take over manufacturing and marketing of Afrezza, but Sanofi said it was dropping the effort in January 2016 due to poor sales of US$7.5 million in 2015; the companies formally terminated the agreement in November 2016. At the time that Sanofi announced it was dropping the product Mannkind said it would continue alone, and it had taken over manufacturing and relaunched the drug by July 2016.

In July 2025, Karoline Leavitt, the White House press secretary, stated that Trump had been diagnosed with chronic venous insufficiency. Trump's physician, Barbabella, wrote in a statement that bruising on Trump's right hand was attributed to his use of aspirin and frequent hand-shaking. It was later noted, however, that vascular tests confirmed that Trump in fact had swelling in his legs at the time of his diagnosis. Large bruises continued to appear on Trump's hands in August through December of 2025 and in 2026. On August 27, 2025, Vice President JD Vance stated that he was ready to become president; this led to speculation that Trump was seriously ill or dead. That day, he was seen leaving for golf, but a photo which Trump shared of himself on August 31 was determined to have potentially been taken on August 23, fueling further speculation of continuing health concerns. Increased discussion about his mental health occurred in August. A photograph of Trump leaving the White House on September 1 confirmed he was still alive, but led to more speculation about his health due to seeming changes in his appearance. Theories alleging that Trump suffered an ischemic stroke grew following the photos' release; Trump disputed suggestions that he suffered ill health, asserting that he "never felt better in [his] life" in an all-caps Truth Social post. On September 11, during a 9/11 commemoration at the Pentagon, the right side of Trump's face was said to droop down heavily, once again sparking concerns of a stroke.

Although some worms have eyes (e.g. leeches, some polychaetes), earthworms do not. However, they do have specialized photosensitive cells called "light cells of Hess". These photoreceptor cells have a central intracellular cavity (phaosome) filled with microvilli. As well as the microvilli, there are several sensory cilia in the which are structurally independent of the microvilli. The photoreceptors are distributed in most parts of the epidermis, but are more concentrated on the back and sides of the worm. A relatively small number occur on the ventral surface of the first segment. They are most numerous in the prostomium, and reduce in density in the first three segments; they are very few in number past the third segment.

The result would be a higher frequency of the allele responsible for the His-variant enzyme in regions that had been under selective pressure the longest. The distribution and frequency of the His variant follows the spread of rice cultivation to inland regions of Asia, with higher frequencies of the His variant in regions that have cultivated rice the longest. The geographic distribution of the alleles seems to therefore be a result of natural selection against individuals with lower reproductive success, namely, those who carried the Arg variant allele and were more susceptible to alcoholism. However, the persistence of the Arg variant in other populations argues that the effect could not be strong.

Total land sales amounted to around half the area of the state of Saxony-Anhalt. At the end of 2007, it still owned over 500,000 hectares (1,200,000 acres) of agricultural land and just under 100,000 hectares (250,000 acres) of forest land.

Sources: en.wikipedia.org

Reference notes

Pan-Slavism in the south, largely advocated by Serbs, would often turn to Russia for support. The Southern Slavic movement advocated the independence of the Slavic peoples in the Austro-Hungarian Empire, Republic of Venice and the Ottoman Empire. Most Serbian intellectuals sought to unite all of the Southern, Balkan Slavs, whether Catholic (Croats, Slovenes), Muslim (Bosniaks, Pomaks), or Orthodox (Montenegrins, Serbs, Macedonians, Bulgarians) as a "Southern-Slavic nation of three faiths". Austria feared that Pan-Slavists would endanger the empire. In Austria-Hungary Southern Slavs were distributed among several entities: Slovenes in the Austrian part (Carniola, Styria, Carinthia, Gorizia and Gradisca, Trieste, Istria), Croats and Serbs in the Hungarian part within the autonomous Kingdom of Croatia-Slavonia and in the Austrian part within the autonomous Kingdom of Dalmatia, and in Bosnia and Herzegovina, under direct control from Vienna. Owing to a different position within Austria-Hungary, several different goals were prominent among the Southern Slavs of Austria-Hungary. A strong alternative to Pan-Slavism was Austroslavism, especially among the Croats and Slovenes. Because the Serbs were dispersed among several regions, and the fact that they had ties to the independent nation state of Kingdom of Serbia, they were among the strongest supporters of independence of South-Slavs from Austria-Hungary and uniting into a common state under Serbian monarchy.

Irregularities were also reported on election day, with the election observation platform Vote62 receiving over 5,000 reports from citizens. In Chonburi Constituency 1, a large crowd gathered on 9 February to demand a recount following allegations of irregularities, including misplaced and improperly sealed ballot boxes, power outages during vote counting, vote total discrepancies, and vote tally sheets being found in a rubbish bin. The crowd remained guarding the ballot boxes overnight awaiting a decision by the Election Commission, which after a meeting asked for two days to gather and consider evidence before determining whether there would be a recount. A similar incident of crowds gathering to ask for a recount and guarding ballot boxes also occurred in Maha Sarakham Constituency 1. Following these and similar allegations, the People's Party formally requested recounts in 18 constituencies. One of its former MPs, Wiroj Lakkhanaadisorn, filed a police report against members of the Election Commission in Chonburi. The Pheu Thai Party also urged the Election Commission to investigate and address the concerns. Korn Chatikavanij, deputy leader of the Democrat Party, criticized the Election Commission, expressing disappointment that citizens were unable to feel trust in the election process. Pirapan Salirathavibhaga, the leader of the United Thai Nation Party, posted on his Facebook account demanding a nationwide recount.

High-level waste (HLW) is produced by nuclear reactors and the reprocessing of nuclear fuel. The exact definition of HLW differs internationally. After a nuclear fuel rod serves one fuel cycle and is removed from the core, it is considered HLW. Spent fuel rods contain mostly uranium with fission products and transuranic elements generated in the reactor core. Spent fuel is highly radioactive and often hot. HLW accounts for over 95% of the total radioactivity produced in the process of nuclear electricity generation but it contributes to less than 1% of volume of all radioactive waste produced in the UK. Overall, the 60-year-long nuclear program in the UK up until 2019 produced 2150 m3 of HLW. The radioactive waste from spent fuel rods consists primarily of cesium-137 and strontium-90, but it may also include plutonium, which can be considered transuranic waste. The half-lives of these radioactive elements can differ quite extremely. Some elements, such as cesium-137 and strontium-90 have half-lives of approximately 30 years. Meanwhile, plutonium has a half-life that can stretch to as long as 24,000 years. The amount of HLW worldwide is increasing by about 12,000 tonnes per year. A 1000-megawatt nuclear power plant produces about 27 tonnes of spent nuclear fuel (unreprocessed) every year. For comparison, the amount of ash produced by coal power plants in the United States is estimated at 130,000,000 t per year and fly ash is estimated to release 100 times more radiation than an equivalent nuclear power plant.

Protamine zinc insulin (PZI) is the name of a slight variation of NPH insulin that includes zinc, which is similar to lente. It is used for cats and dogs. It is manufactured by Boehringer Ingelheim Animal Health under the name ProZinc.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

Network